ecancermedicalscience

Erratum

METNET: a phase II trial of metformin in patients with well-differentiated neuroendocrine tumours

João Glasberg1,2, Aley Talans3,4, Thomás Rivelli Giollo1, Débora Zachello Recchimuzzi1, João Evangelista Bezerra Neto1, Rossana Veronica Mendonza Lopez5, Paulo Marcelo Gehm Hoff1 and Rachel P Riechelmann2,6

ecancer 16 1369 (2022) https://doi.org/10.3332/ecancer.2022.1369

1Department of Clinical Oncology, Instituto do Câncer do Estado de São Paulo, Faculdade de Medicina da Universidade de São Paulo – FMUSP, São Paulo, Brazil

2Post Graduate Program, Faculdade de Medicina da Universidade de São Paulo, Brazil

3Department of Medical Radiology, Fleury Group, São Paulo, Brazil

4Department of Medical Radiology, Hospital Israelita Albert Einstein, São Paulo, Brazil

5Center for Translational Research in Oncology, Instituto do Câncer do Estado de São Paulo, Faculdade de Medicina da Universidade de São Paulo – FMUSP, São Paulo, Brazil

6Department of Clinical Oncology, AC Camargo Cancer Center, São Paulo, Brazil


Keywords: neuroendocrine tumours, metformin, cancer treatment

Correspondence to: Rachel P Riechelmann
Email: rachel.riechelmann@accamargo.org.br

Published: 04/07/2022
Received: 14/06/2022

Publication costs for this article were supported by ecancer (UK Charity number 1176307).

Copyright: © the authors; licensee ecancermedicalscience. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Thomás Rivelli Giollo is corrected to Thomás Giollo Rivelli

Artículos relacionados

Lo sentimos, esta búsqueda no pudo encontrar ningún artículo - por favor intente una búsqueda diferente.

Table of Contents
Table of Contents